1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

<table>
<thead>
<tr>
<th>Pfizer Inc</th>
<th>Pfizer Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pharmaceuticals Group</td>
<td>Ramsgate Road</td>
</tr>
<tr>
<td>235 East 42nd Street</td>
<td>Sandwich, Kent</td>
</tr>
<tr>
<td>New York, New York 10017</td>
<td>CT13 9NJ</td>
</tr>
<tr>
<td>1-212-573-2222</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300</td>
<td>Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322</td>
</tr>
<tr>
<td>Contact E-Mail: <a href="mailto:pfizer-MSDS@pfizer.com">pfizer-MSDS@pfizer.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Material Name: Latanoprost Solution

| Trade Name: | Xalatan Sterile Ophthalmic Solution |
| Chemical Family: | Mixture |
| Intended Use: | Pharmaceutical product used for glaucoma |

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless to slightly yellow solution

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

| Short Term: | May cause eye irritation. Not expected to cause skin irritation. Accidental ingestion may cause effects similar to those seen in clinical use. |
| Long Term: | Animal studies have shown a potential to cause adverse effects on the fetus. |

Known Clinical Effects: Nausea, abdominal discomfort, headache, dizziness, sweating, fatigue, change in eye color, change in eyelash color, change in eyelid color.

EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

LATANOPROST SOLUTION
3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latanoprost</td>
<td>130209-82-4</td>
<td>Not listed</td>
<td>Repr.Cat.3,R63</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Benzalkonium chloride</td>
<td>8001-54-5</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Phosphate Monobasic, Monohydrate</td>
<td>10049-21-5</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Carbon dioxide, carbon monoxide

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
### Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:**
Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Storage Conditions:**
Store as directed by product packaging.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

**Latanoprost**
- **Pfizer OEL TWA-8 Hr:** 0.7µg/m³

**Sodium chloride**
- **Latvia OEL - TWA:** Listed
- **Lithuania OEL - TWA:** Listed

**Engineering Controls:**
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Environmental Exposure Controls:**
Refer to specific Member State legislation for requirements under Community environmental legislation.

**Personal Protective Equipment:**
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- **Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- **Eyes:** Wear safety glasses or goggles if eye contact is possible.
- **Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- **Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Physical State:** Liquid
- **Molecular Formula:** Mixture
- **Color:** Colorless to light yellow
- **Molecular Weight:** Mixture

### 10. STABILITY AND REACTIVITY

- **Stability:** Stable at normal conditions
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
10. STABILITY AND REACTIVITY
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Latanoprost
Rat Oral LD 50 > 50 mg/kg
Rat Intravenous LD 50 > 2 mg/kg
Mouse Oral LD50 > 50 mg/kg

Sodium chloride
Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Benzalkonium chloride
Rat Oral LD50 240 mg/kg

Sodium phosphate, dibasic
Rat Oral LD 50 17 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Latanoprost
Skin Irritation Rabbit Slight
Eye Irritation Rabbit No effect
Skin Sensitization - GPMT Guinea Pig Negative
Antigenicity- Passive cutaneous anaphylaxis Mouse Negative
Antigenicity- Passive cutaneous anaphylaxis Guinea Pig Negative

Sodium chloride
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Benzalkonium chloride
Skin Irritation Rabbit Moderate
Eye Irritation Rabbit Severe

Sodium phosphate, dibasic
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Latanoprost
28 Day(s) Rat Oral 0.2 mg/kg/day NOAEL None identified
13 Week(s) Rat Oral 0.2 mg/kg/day NOAEL None identified
13 Week(s) Dog Intravenous 0.001 mg/kg/day NOAEL None identified

LATANOPROST SOLUTION
11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Latanoprost
Fertility and Embryonic Development  Rabbit  Intravenous  0.001 mg/kg/day  NOAEL  Embryotoxicity
Reproductive & Fertility  Rat  Intravenous  0.035 mg/kg/day  NOAEL  Paternal toxicity, Not Teratogenic
Prenatal & Postnatal Development  Rat  Intravenous  0.01 mg/kg/day  NOAEL  No effects at maximum dose
Embryo / Fetal Development  Rat  Intravenous  0.05 mg/kg/day  NOAEL  Paternal toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Latanoprost
Bacterial Mutagenicity (Ames)  Bacteria  Negative
In Vitro Mammalian Cell Mutagenicity  Mouse Lymphoma  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Positive without activation
In Vivo Unscheduled DNA Synthesis  Rat Hepatocyte  Negative
In Vivo Micronucleus  Mouse Bone Marrow  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Latanoprost
80 Month(s)  Mouse  Oral  0.2 mg/kg/day  NOAEL  Not carcinogenic
2 Year(s)  Rat  Oral  0.2 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified
### 15. REGULATORY INFORMATION

**OSHA Label:**
Non-hazardous in accordance with international standards for workplace safety.

**Canada - WHMIS: Classifications**

WHMIS hazard class:
None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Standard for the Uniform Scheduling for Drugs and Poisons:</th>
<th>Australia (AICS): List</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latanoprost</td>
<td>Schedule 4</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium Phosphate Monobasic, Monohydrate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzalkonium chloride</td>
<td>Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Listed</td>
<td></td>
<td>231-598-3</td>
</tr>
<tr>
<td>Water</td>
<td>Listed</td>
<td></td>
<td>231-791-2</td>
</tr>
</tbody>
</table>
16. OTHER INFORMATION

Full text of S3 R phrases
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet